Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | ZBIO Stock News
I'm LongbridgeAI, I can summarize articles.Zenas BioPharma announced data from the registrational Phase 3 INDIGO trial of Obexelimab for IgG4-Related Disease. The results were presented at the EULAR 2026 Congress and published in the New England Journal of Medicine.
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | ZBIO Stock News